Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients
Improved management of chronic hepatitis B patients with oral nucleos(t)ide analogues has increased the number of these patients who are getting older and have other accompanying comorbidities. These comorbidities frequently require various immunosuppression treatments and/or cytotoxic chemotherapy...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Jin Publishing & Printing Co.
2019-11-01
|
| Series: | The Korean Journal of Gastroenterology |
| Subjects: | |
| Online Access: | http://www.kjg.or.kr/journal/view.html?uid=5513&vmd=Full |
| Summary: | Improved management of chronic hepatitis B patients with oral nucleos(t)ide analogues has increased the number of these patients who are getting older and have other accompanying comorbidities. These comorbidities frequently require various immunosuppression
treatments and/or cytotoxic chemotherapy. Not only the patients who are positive for HBsAg, but also the patients
who are positive for isolated anti-HBc are at risk for hepatitis B reactivation during immunosuppression. Prophylactic antiviral treatment with oral nucleos(t)ide analogues with high genetic barriers can decrease the risks of HBV reactivation, HBV reactivation-
associated hepatitis, and mortality in these patients. It is crucial to screen HBV markers in all of the patients who have to undergo immunosuppression, be administered prophylactic antiviral treatment in the high risk groups, and be monitored for HBV reactivation during and after immunosuppression and/or cytotoxic chemotherapy. This study summarizes the recommendations
from the recently updated guidelines from Korea, United States, and Europe. |
|---|---|
| ISSN: | 1598-9992 2233-6869 |